Number of responders and non-responders at maximum effect and measurement points in High/Low-IFX group.

Nakae, Kazuto; Masui, Sho; Yonezawa, Atsushi; Hashimoto, Motomu; Watanabe, Ryu; Murata, Koichi; Murakami, Kosaku; Tanaka, Masao; Ito, Hiromu; Yokoyama, Kotoko; Iwamoto, Noriko; Shimada, Takashi; Nakamura, Miyuki; Denda, Masaya; Itohara, Kotaro; Nakagawa, Shunsaku; Ikemi, Yasuaki; Imai, Satoshi; Nakagawa, Takayuki; Hayakari, Makoto; Matsubara, Kazuo

doi:10.1371/journal.pone.0258601.s002

pone.0258601.s002.docx (41.59 kB)

Number of responders and non-responders at maximum effect and measurement points in High/Low-IFX group.

journal contribution

posted on 2021-10-13, 17:33 authored by Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara

The cut-off value was determined to be at serum IFX level ≥1.0 μg/mL. Responders had “good and moderate responses” and non-responders had “no responses” based on the EULAR response criteria. Values were considered statistically significant at a p value less than 0.05, based on two-sided Fisher’s exact test. Abbreviations: EULAR, European League Against Rheumatism; IFX, infliximab.

(DOCX)